What is PLA2R and Its Role in Kidney Disease?

PLA2R, short for M-type phospholipase A2 receptor, is a protein found on the surface of podocytes, the specialized cells that form the kidney’s filtering barrier. It became one of the most important molecules in nephrology after a landmark 2009 study revealed it as the primary target of an autoimmune attack in membranous nephropathy, a leading cause of nephrotic syndrome in adults. Roughly three-quarters of people with primary membranous nephropathy carry antibodies against PLA2R in their blood, and that single discovery reshaped how the disease is diagnosed, monitored, and treated.

How PLA2R Was Identified as the Key Target

For decades, membranous nephropathy was a frustrating diagnosis. Doctors could see immune deposits clogging the kidney’s filtration membrane on biopsy, but nobody knew what the immune system was attacking. In 2009, researchers led by Laurence Beck and David Bhave at Boston University tested serum from patients with idiopathic (primary) membranous nephropathy against glomerular protein extracts. About 70% of those patients’ blood samples reacted with a single large protein that mass spectrometry identified as PLA2R. The antibodies were predominantly of the IgG4 subclass, matching the type of immunoglobulin typically found in kidney biopsy deposits from these patients.¹ None of the patients with secondary membranous nephropathy (caused by lupus, infections, or drugs) showed this antibody, which immediately hinted that PLA2R antibody testing could distinguish primary from secondary forms of the disease.

Since that discovery, studies across multiple ethnic populations have consistently found anti-PLA2R antibodies in roughly 70 to 80% of patients with primary membranous nephropathy.² That consistency transformed the understanding of primary membranous nephropathy from a mysterious glomerular disease into a renal-limited autoimmune condition with a defined molecular target.

What PLA2R Looks Like and Where It Sits

PLA2R is a large transmembrane glycoprotein. It has a bulky extracellular portion made up of multiple domains, a single stretch that crosses the cell membrane, and a short tail on the inside of the cell.³ It sits on the outer surface of podocytes, the cells whose foot-like projections wrap around kidney capillaries and help control what passes through into urine. The extracellular domains are where the trouble starts: they contain the regions the immune system mistakenly recognizes as foreign.

Cryo-electron microscopy has provided a high-resolution view of PLA2R’s three-dimensional shape, showing that its dominant autoimmune epitope sits in an accessible position at the cell surface. The structure also reveals a unique immunogenic signature that likely explains why the immune system singles out PLA2R for attack rather than similar proteins.⁴

How Anti-PLA2R Antibodies Damage the Kidney

The basic problem in PLA2R-associated membranous nephropathy is straightforward in concept: the immune system produces antibodies that bind to PLA2R on podocytes, and the resulting immune complexes accumulate just beneath the filtration barrier. That accumulation triggers complement activation, a cascade of immune proteins that injures the podocyte and makes the filter leak protein into the urine.

Animal models have confirmed this chain of events. Mice engineered to express human PLA2R on their podocytes spontaneously developed anti-PLA2R antibodies, followed by nephrotic-range protein in the urine, high cholesterol, and the characteristic biopsy findings of membranous nephropathy, including granular immune deposits beneath the epithelium.⁵ These mice essentially developed the human disease on their own, without any injection of pre-formed antibodies.

Recent work has added a mechanistic wrinkle. Anti-PLA2R antibodies accelerate the shedding of PLA2R’s extracellular portion from the podocyte surface. That shed fragment anchors to the glomerular basement membrane and serves as a landing pad for more antibodies, amplifying the local immune deposit.⁶ In other words, the antibodies help create the very conditions that trap more antibodies in the kidney.

The complement side of the story has also grown more nuanced. Individual antibodies binding to a single spot on PLA2R do not efficiently trigger the complement cascade on their own. But when pairs of antibodies target two different regions of PLA2R simultaneously, complement activation ramps up dramatically. IgG1 and IgG3 subclass antibodies are the strongest complement activators in this pairing scheme, while IgG4, the dominant subclass in membranous nephropathy deposits, actually dampens complement activation when it is present alongside IgG1.⁷ This suggests the balance among antibody subclasses and the regions they target may determine how aggressively the disease behaves.

Epitope Spreading and Disease Severity

Not all anti-PLA2R antibodies are created equal. PLA2R has several distinct domains that the immune system can target, and the pattern of which domains are targeted turns out to matter a great deal for prognosis.

The earliest and most common antibody response is directed at a single domain called CysR (the cysteine-rich domain). Patients whose antibodies remain restricted to CysR tend to be younger, have less severe protein loss, and are more likely to go into spontaneous remission. When the immune response expands to include additional domains, such as CTLD1 and CTLD7, a phenomenon called epitope spreading, outcomes worsen. Epitope spreading beyond CysR was an independent predictor of both kidney function decline and progression to end-stage kidney disease in a study that followed patients over time.⁸ Conversely, when the immune response contracted back to CysR-only during follow-up, the patient’s disease improved.

Domain-specific antibody testing can also predict how well a patient responds to treatment. In patients treated with cyclophosphamide, differences in antibody levels against the CysR, CTLD1, and CTLD678 domains distinguished responders from non-responders.⁹ This kind of profiling is still mostly a research tool, but it is gradually moving toward clinical practice as a way to tailor treatment intensity to the underlying immunological activity.

Diagnosis Without a Biopsy

Before anti-PLA2R testing existed, diagnosing membranous nephropathy required a kidney biopsy, an invasive procedure that carries a small but real risk of bleeding. The availability of a blood test for anti-PLA2R antibodies has changed that calculus for some patients.

A meta-analysis pooling data from multiple studies found that serum anti-PLA2R testing had a sensitivity of about 68% and a specificity of 97% for distinguishing primary from secondary membranous nephropathy.¹⁰ That very high specificity means a positive result is strongly reliable: when the blood test is positive, it almost certainly indicates primary disease. The modest sensitivity, however, means a negative blood test does not rule it out. A substantial minority of patients with genuine primary membranous nephropathy will test negative in the blood, either because their antibody levels are low or because their disease targets a different antigen entirely.

Staining kidney biopsy tissue for PLA2R protein catches some of those seronegative cases. Glomerular PLA2R staining has a higher sensitivity (around 78 to 81%) but somewhat lower specificity than the blood test.¹¹ For this reason, guidelines recommend tissue staining in patients who test negative in the blood but are clinically suspected of having primary membranous nephropathy.

When can a biopsy be safely skipped? In patients who have preserved kidney function, test positive for anti-PLA2R antibodies at meaningful levels, and have no signs of secondary causes like lupus or cancer, some experts argue that a biopsy is unnecessary.¹² Low-level positive results need confirmation with a secondary method. And if kidney function is significantly impaired, a biopsy remains important because it can reveal additional disease processes happening alongside membranous nephropathy. A large Chinese cohort study reinforced this approach but noted that complicating diseases appeared more frequently in that population, suggesting the decision to skip biopsy should be individualized rather than universal.¹³

Tracking Treatment Response Through Antibody Levels

One of the most clinically useful properties of anti-PLA2R antibodies is that their levels in the blood change faster than the clinical markers doctors traditionally rely on. Proteinuria, the hallmark of membranous nephropathy, can take many months to improve after treatment, leaving clinicians uncertain about whether a drug is working. Anti-PLA2R antibody levels, by contrast, begin dropping sooner. Changes in antibody levels preceded changes in proteinuria in patients treated with rituximab, the B-cell-depleting drug that has become a first-line treatment for this disease.¹⁴

The prognostic value of antibody monitoring after rituximab is striking. In one study, lower antibody levels at the start of treatment and complete antibody clearance by six months both strongly predicted that the patient would eventually enter remission. Every patient who achieved complete remission had first cleared their anti-PLA2R antibodies. On average, a 50% drop in antibody levels preceded an equivalent drop in proteinuria by about ten months. Perhaps most useful for long-term management, the re-emergence of circulating antibodies after initial clearance predicted disease relapse.¹⁵

Even in the absence of treatment, antibody levels at diagnosis carry information. Spontaneous remission occurs in roughly a fifth of patients with membranous nephropathy, and the likelihood of remission is closely correlated with the initial antibody titer in a dose-response pattern: lower levels at diagnosis mean better odds of remission without treatment.¹⁶

Rituximab and PLA2R-Guided Therapy

Rituximab has emerged as a central treatment for PLA2R-associated membranous nephropathy, and antibody monitoring has become tightly interwoven with how the drug is used. Rituximab works by depleting B cells, the immune cells responsible for producing antibodies. In patients with membranous nephropathy, this translates to a drop in anti-PLA2R production, followed by gradual improvement in kidney function.

Even in patients with advanced chronic kidney disease, where treatment options historically seemed limited, rituximab can achieve meaningful results. In a study of patients with severe kidney impairment, rituximab led to improved filtration rates and remission of nephrotic syndrome in the majority of treatment courses after a median follow-up of about three and a half years. Immunological remission, meaning clearance of anti-PLA2R antibodies, preceded clinical improvement and predicted who would respond.¹⁷ This pattern reinforces the idea that antibody monitoring is not just a diagnostic curiosity but a practical tool for real-time treatment decisions.

The Genetic Underpinnings

Membranous nephropathy does not strike randomly. Genome-wide association studies have identified two genetic regions that strongly predispose people to PLA2R-associated disease. One is on chromosome 2, in the gene encoding PLA2R itself. The other is on chromosome 6, in the HLA-DQA1 gene, which is part of the immune system’s machinery for presenting protein fragments to T cells.¹⁸ The combination makes biological sense: one gene encodes the target, and the other influences how the immune system processes and responds to that target.

This genetic association has been replicated in Chinese, South Asian, and European populations.¹⁹²⁰ Risk alleles at both loci interact with each other and are closely tied to the presence of circulating anti-PLA2R antibodies and PLA2R deposits in kidney tissue. Having risk alleles at both loci amplifies susceptibility more than either allele alone, pointing to a gene-gene interaction rather than two independent effects.

Environmental factors may also play a role. Research from China has linked long-term exposure to high levels of fine particulate air pollution (PM2.5) with increased odds of developing primary membranous nephropathy, particularly in heavily polluted regions.²¹ This finding is still being investigated, but it suggests that genetic susceptibility may interact with environmental exposures to trigger the autoimmune response against PLA2R.

PLA2R and Kidney Transplantation

When membranous nephropathy progresses to kidney failure and a patient receives a transplant, the disease can recur in the new kidney. This happens because the autoimmune attack is driven by circulating antibodies, not by something inherent to the original kidney. The transplanted organ expresses PLA2R on its podocytes just like the native kidney did, making it a fresh target.

Patients who have detectable anti-PLA2R antibodies before transplantation face a markedly higher risk of disease recurrence. A study found the risk was roughly six times higher in antibody-positive patients compared to those who were antibody-negative before surgery.²² This has led to growing interest in treating transplant candidates before surgery to drive antibody levels down and reduce the risk of losing the new graft. Case reports have described using rituximab or other immunosuppressants before transplantation specifically to achieve serological remission, with the goal of improving long-term graft survival.²³

When PLA2R Is Not Involved

About 20 to 30% of patients with primary membranous nephropathy test negative for PLA2R antibodies. Their disease is real, but the immune system is targeting something else. Over the past several years, researchers have identified a growing list of alternative antigens.

THSD7A (thrombospondin type 1 domain-containing 7A) was the second target antigen discovered and accounts for a small fraction of PLA2R-negative cases. More recently, NELL-1 has emerged as a notable antigen. In one Chinese cohort, NELL-1 was found in about 35% of patients who were negative for both PLA2R and THSD7A. Most NELL-1-positive patients were women, and their antibody profile differed slightly from PLA2R-positive patients in the balance of IgG subtypes.²⁴ Other rare antigens include PCDH7 and NCAM-1, though these were uncommon even in large cohorts.²⁵

The identification of these antigens is shifting the field toward an antigen-based classification system for membranous nephropathy rather than the traditional primary-versus-secondary split. Each antigen may eventually carry its own prognostic and therapeutic implications, though research is still early for most of them.

PLA2R in Children

Membranous nephropathy is uncommon in children, and when it does occur, PLA2R plays a much smaller role than it does in adults. In one large pediatric series, only about 38% of children with membranous nephropathy had PLA2R-positive disease, compared to the 60 to 80% rate seen in adults.²⁶ Age within childhood also matters: adolescents are far more likely to be PLA2R-positive than younger children. In one study, about 82% of adolescents with the disease stained positive for PLA2R in their kidney biopsies, compared to only about 26% of younger children.²⁷

This age-related gradient suggests that the autoimmune process targeting PLA2R either takes time to develop or is influenced by hormonal and immune maturation factors that differ between childhood and adulthood. It also means that pediatric membranous nephropathy may be driven by different antigens in many cases, and that diagnostic approaches validated in adults cannot be directly transferred to children without adjustment. For younger children in particular, a negative PLA2R test provides much less reassurance than it does in an adult, and a biopsy with comprehensive antigen staining is generally more important.